Redesign Science

Redesign Science is a New York-based platform biotechnology company that simulates biomolecular systems from first principles using physics-based, atomic-level molecular dynamics. Its NUVO technology platform integrates physics simulation, chemistry and synthetic data with generative AI, and is applied to the company's internal therapeutics pipeline. The company develops first-in-class small molecule Targeted Protein Interaction Modulators (TPIM), targeting the structural protein interactome in order to control cellular biology with small molecules.

Technically, the company has focused on algorithms that fuse molecular dynamics, statistical physics and machine learning to analyze a protein's structural dynamics quickly, with the stated premise that the complex equilibria of protein systems can be characterized through mixed simulation modes to reveal drug sites that are not visible in static protein structure analysis. It has built a virtual small molecule design framework that combines discovery of dynamic drug sites with the thermodynamics and kinetics of drug binding. Reported applications span precision cancer therapeutics and first-in-class small molecules for inflammatory bowel disease, and the company describes progress in multiple first-in-class targeted therapy programs.

Founding story

The company is associated with NYU and NYU Langone Health's technology venturing portfolio, where David Rooklin, PhD, is listed as principal investigator [5]. Cofounders identified in press coverage are David Rooklin (CEO) and Haotian Li (CTO) [2][4].

Business model

The company positions itself as a platform technology company that applies its computational platform to an internal pipeline of small-molecule assets while also pursuing strategic co-development partnerships with biotech firms. Following its 2021 seed financings, it stated it would continue advancing co-development partnerships and launch an internal pipeline of early stage asset development [2].

Traction

By December 2021 the company reported having identified early hits for several emerging and challenging target classes, spanning precision cancer therapeutics and first-in-class small molecules for inflammatory bowel disease, and had completed $15 million in Seed-2 and Seed-3 financings [2][4]. Its website reports progress in multiple first-in-class targeted therapy programs using NUVO [0][1]. One source lists headcount in the 11-50 range [6].